Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology ...
BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...
Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...
Scientists in southern China have developed a new strategy to fight cancer by forcing tumor cells to "expose themselves" to ...
ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...
SurvivorNet on MSN
Cancer patients are living longer — a closer look at the treatments driving this progress
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
The result is one molecule that can be both a checkpoint degrader and a cancer vaccine ( Nature 2026, DOI: 10.1038/s41586-025 ...
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...
Alshehri, E. (2026) The Diagnostic Conundrum of Recurrent High-Grade Vaginal Intraepithelial Neoplasia (VAIN) Following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback